MedTrace Logo

Artificial Intelligence Guided Personalised Medicine in Patients With Hypertension and Diabetes

NCT04769141 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-07-22

No results posted yet for this study

Summary

Hypertension and diabetes are chronic diseases that require long-term management and disease control is often sub-optimal, leading to complications which place additional burden on patients and the healthcare system.

This study aims to address factors such as gender, ethnicity and specific genetics that are not routinely considered during drug dosing but account for considerable variations in drug responses by tailoring the treatment to individual patient using CURATE.AI. CURATE.AI is an artificial intelligence guided dosing decision tool and can be applicable across many different conditions, as it is disease agnostic. This platform had demonstrated initial success in cancer and transplant populations but has yet to be applied to chronic disease patients.

The aim of this study is demonstrate that artificial intelligence guided treatment in chronic disease of hypertension and type 2 diabetes mellitus will yield actionable medication dosing optimization.

Conditions

Interventions

COMBINATION_PRODUCT

CURATE.AI

CURATE.AI is one example of an artificial intelligence guided dosing decision tool. It is customized to each individual and can be applicable across many different conditions, as it is disease agnostic. This platform has already demonstrated initial success in cancer and transplant populations but yet to be applied to chronic disease patients.

Sponsors & Collaborators

  • Alexandra Hospital

    lead OTHER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2021-12-31
Completion
2023-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04769141 on ClinicalTrials.gov